Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand white rabbits (oryctolagus cuniculus)

Megan K. Watson, Luke Anthony Wittenburg, Christine T. Bui, Kira A. Jarosz, Daniel L. Gustafson, Matthew S. Johnston

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE To evaluate the pharmacokinetics and bioavailability of 2 doses of orbifloxacin in rabbits. ANIMALS 6 healthy purpose-bred adult female New Zealand White rabbits (Oryctolagus cuniculus). PROCEDURES Each of 3 rabbits received orbifloxacin at either 10 or 20 mg/kg, PO. Then, after a 1-week washout period, they received the same dose IV. Blood samples were collected from each rabbit at 0, 0.25, 0.5, 1, 2, 4, 6, 12, and 24 hours after drug administration. Plasma orbifloxacin concentration was measured with liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters were determined by noncompartmental analysis for data obtained following PO administration and noncompartmental and compartmental analyses for data obtained following IV administration. RESULTS Following oral administration, the mean ± SD peak plasma orbifloxacin concentration was 1.66 ± 0.51 mg/mL for rabbits administered the 10 mg/kg dose and 3.00 ± 0.97 μg/mL for rabbits administered the 20 mg/kg dose and was attained at 2 hours after drug administration. The mean ± SD half-life of orbifloxacin in plasma was 7.3 ± 1.1 hours for rabbits administered the 10 mg/ kg dose and 8.6 ± 0.55 hours for rabbits administered the 20 mg/kg dose. Mean bioavailability was 52.5% for rabbits administered the 10 mg/kg dose and 46.5% for rabbits administered the 20 mg/kg dose. CONCLUSIONS AND CLINICAL RELEVANCE Results provided pharmacokinetic properties for 2 doses (10 mg/kg and 20 mg/kg) of orbifloxacin oral suspension in rabbits. Further studies are necessary to determine the protein-binding activity of orbifloxacin in rabbits before dosages for the treatment of common pathogens in this species are recommended.

Original languageEnglish (US)
Pages (from-to)946-951
Number of pages6
JournalAmerican Journal of Veterinary Research
Volume76
Issue number11
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

New Zealand White rabbit
Oryctolagus cuniculus
Biological Availability
pharmacokinetics
bioavailability
mouth
Suspensions
Pharmacokinetics
rabbits
Rabbits
dosage
orbifloxacin
drugs
protein binding
intravenous injection
oral administration
half life
data analysis
Protein Binding
Pharmaceutical Preparations

ASJC Scopus subject areas

  • veterinary(all)
  • Medicine(all)

Cite this

Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand white rabbits (oryctolagus cuniculus). / Watson, Megan K.; Wittenburg, Luke Anthony; Bui, Christine T.; Jarosz, Kira A.; Gustafson, Daniel L.; Johnston, Matthew S.

In: American Journal of Veterinary Research, Vol. 76, No. 11, 01.11.2015, p. 946-951.

Research output: Contribution to journalArticle

Watson, Megan K. ; Wittenburg, Luke Anthony ; Bui, Christine T. ; Jarosz, Kira A. ; Gustafson, Daniel L. ; Johnston, Matthew S. / Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand white rabbits (oryctolagus cuniculus). In: American Journal of Veterinary Research. 2015 ; Vol. 76, No. 11. pp. 946-951.
@article{e11197e7ae27481bb829e7e6f1d5f097,
title = "Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand white rabbits (oryctolagus cuniculus)",
abstract = "OBJECTIVE To evaluate the pharmacokinetics and bioavailability of 2 doses of orbifloxacin in rabbits. ANIMALS 6 healthy purpose-bred adult female New Zealand White rabbits (Oryctolagus cuniculus). PROCEDURES Each of 3 rabbits received orbifloxacin at either 10 or 20 mg/kg, PO. Then, after a 1-week washout period, they received the same dose IV. Blood samples were collected from each rabbit at 0, 0.25, 0.5, 1, 2, 4, 6, 12, and 24 hours after drug administration. Plasma orbifloxacin concentration was measured with liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters were determined by noncompartmental analysis for data obtained following PO administration and noncompartmental and compartmental analyses for data obtained following IV administration. RESULTS Following oral administration, the mean ± SD peak plasma orbifloxacin concentration was 1.66 ± 0.51 mg/mL for rabbits administered the 10 mg/kg dose and 3.00 ± 0.97 μg/mL for rabbits administered the 20 mg/kg dose and was attained at 2 hours after drug administration. The mean ± SD half-life of orbifloxacin in plasma was 7.3 ± 1.1 hours for rabbits administered the 10 mg/ kg dose and 8.6 ± 0.55 hours for rabbits administered the 20 mg/kg dose. Mean bioavailability was 52.5{\%} for rabbits administered the 10 mg/kg dose and 46.5{\%} for rabbits administered the 20 mg/kg dose. CONCLUSIONS AND CLINICAL RELEVANCE Results provided pharmacokinetic properties for 2 doses (10 mg/kg and 20 mg/kg) of orbifloxacin oral suspension in rabbits. Further studies are necessary to determine the protein-binding activity of orbifloxacin in rabbits before dosages for the treatment of common pathogens in this species are recommended.",
author = "Watson, {Megan K.} and Wittenburg, {Luke Anthony} and Bui, {Christine T.} and Jarosz, {Kira A.} and Gustafson, {Daniel L.} and Johnston, {Matthew S.}",
year = "2015",
month = "11",
day = "1",
doi = "10.2460/ajvr.76.11.946",
language = "English (US)",
volume = "76",
pages = "946--951",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand white rabbits (oryctolagus cuniculus)

AU - Watson, Megan K.

AU - Wittenburg, Luke Anthony

AU - Bui, Christine T.

AU - Jarosz, Kira A.

AU - Gustafson, Daniel L.

AU - Johnston, Matthew S.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - OBJECTIVE To evaluate the pharmacokinetics and bioavailability of 2 doses of orbifloxacin in rabbits. ANIMALS 6 healthy purpose-bred adult female New Zealand White rabbits (Oryctolagus cuniculus). PROCEDURES Each of 3 rabbits received orbifloxacin at either 10 or 20 mg/kg, PO. Then, after a 1-week washout period, they received the same dose IV. Blood samples were collected from each rabbit at 0, 0.25, 0.5, 1, 2, 4, 6, 12, and 24 hours after drug administration. Plasma orbifloxacin concentration was measured with liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters were determined by noncompartmental analysis for data obtained following PO administration and noncompartmental and compartmental analyses for data obtained following IV administration. RESULTS Following oral administration, the mean ± SD peak plasma orbifloxacin concentration was 1.66 ± 0.51 mg/mL for rabbits administered the 10 mg/kg dose and 3.00 ± 0.97 μg/mL for rabbits administered the 20 mg/kg dose and was attained at 2 hours after drug administration. The mean ± SD half-life of orbifloxacin in plasma was 7.3 ± 1.1 hours for rabbits administered the 10 mg/ kg dose and 8.6 ± 0.55 hours for rabbits administered the 20 mg/kg dose. Mean bioavailability was 52.5% for rabbits administered the 10 mg/kg dose and 46.5% for rabbits administered the 20 mg/kg dose. CONCLUSIONS AND CLINICAL RELEVANCE Results provided pharmacokinetic properties for 2 doses (10 mg/kg and 20 mg/kg) of orbifloxacin oral suspension in rabbits. Further studies are necessary to determine the protein-binding activity of orbifloxacin in rabbits before dosages for the treatment of common pathogens in this species are recommended.

AB - OBJECTIVE To evaluate the pharmacokinetics and bioavailability of 2 doses of orbifloxacin in rabbits. ANIMALS 6 healthy purpose-bred adult female New Zealand White rabbits (Oryctolagus cuniculus). PROCEDURES Each of 3 rabbits received orbifloxacin at either 10 or 20 mg/kg, PO. Then, after a 1-week washout period, they received the same dose IV. Blood samples were collected from each rabbit at 0, 0.25, 0.5, 1, 2, 4, 6, 12, and 24 hours after drug administration. Plasma orbifloxacin concentration was measured with liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters were determined by noncompartmental analysis for data obtained following PO administration and noncompartmental and compartmental analyses for data obtained following IV administration. RESULTS Following oral administration, the mean ± SD peak plasma orbifloxacin concentration was 1.66 ± 0.51 mg/mL for rabbits administered the 10 mg/kg dose and 3.00 ± 0.97 μg/mL for rabbits administered the 20 mg/kg dose and was attained at 2 hours after drug administration. The mean ± SD half-life of orbifloxacin in plasma was 7.3 ± 1.1 hours for rabbits administered the 10 mg/ kg dose and 8.6 ± 0.55 hours for rabbits administered the 20 mg/kg dose. Mean bioavailability was 52.5% for rabbits administered the 10 mg/kg dose and 46.5% for rabbits administered the 20 mg/kg dose. CONCLUSIONS AND CLINICAL RELEVANCE Results provided pharmacokinetic properties for 2 doses (10 mg/kg and 20 mg/kg) of orbifloxacin oral suspension in rabbits. Further studies are necessary to determine the protein-binding activity of orbifloxacin in rabbits before dosages for the treatment of common pathogens in this species are recommended.

UR - http://www.scopus.com/inward/record.url?scp=84946018919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946018919&partnerID=8YFLogxK

U2 - 10.2460/ajvr.76.11.946

DO - 10.2460/ajvr.76.11.946

M3 - Article

VL - 76

SP - 946

EP - 951

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 11

ER -